Directed to a key respiratory target for Almirall
The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall.
Under the terms of the agreement, BioFocus, an affiliate of Belgian biotechnology firm Galapagos, will apply its integrated drug discovery capabilities while Spanish pharmaceutical firm Almirall will bring its respiratory expertise to the joint experimental effort.
The value of the collaboration to BioFocus could reach €7.5m.
Dr Bertil Lindmark, chief scientific officer and executive director of r&d at Almirall, said: ‘We selected BioFocus for this alliance because of the excellent technology and scientific fit between both companies.’
Respiratory is a key research focus for Almirall together with gastrointestinal and dermatology areas.